172 related articles for article (PubMed ID: 8589153)
1. Prospects for a vaccine to prevent Lyme disease in humans.
Wormser GP
Clin Infect Dis; 1995 Nov; 21(5):1267-74. PubMed ID: 8589153
[TBL] [Abstract][Full Text] [Related]
2. Lyme disease vaccine.
Wormser GP
Infection; 1996; 24(2):203-7. PubMed ID: 8740123
[TBL] [Abstract][Full Text] [Related]
3. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
[TBL] [Abstract][Full Text] [Related]
4. Vaccination as a modality to prevent Lyme disease. A status report.
Wormser GP
Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
[TBL] [Abstract][Full Text] [Related]
5. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
6. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
7. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.
Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; Pêtre J
Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340
[TBL] [Abstract][Full Text] [Related]
8. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
Sigal LH; Zahradnik JM; Lavin P; Patella SJ; Bryant G; Haselby R; Hilton E; Kunkel M; Adler-Klein D; Doherty T; Evans J; Molloy PJ; Seidner AL; Sabetta JR; Simon HJ; Klempner MS; Mays J; Marks D; Malawista SE
N Engl J Med; 1998 Jul; 339(4):216-22. PubMed ID: 9673299
[TBL] [Abstract][Full Text] [Related]
9. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
10. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH
Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945
[TBL] [Abstract][Full Text] [Related]
11. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
[TBL] [Abstract][Full Text] [Related]
13. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
[TBL] [Abstract][Full Text] [Related]
14. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
[TBL] [Abstract][Full Text] [Related]
15. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
[TBL] [Abstract][Full Text] [Related]
16. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines.
Telford SR; Fikrig E; Barthold SW; Brunet LR; Spielman A; Flavell RA
J Exp Med; 1993 Aug; 178(2):755-8. PubMed ID: 8340764
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to Borrelia burgdorferi infection in the rabbit. Comparison between outer surface protein A vaccine- and infection-derived immunity.
Foley DM; Wang YP; Wu XY; Blanco DR; Lovett MA; Miller JN
J Clin Invest; 1997 Apr; 99(8):2030-5. PubMed ID: 9109448
[TBL] [Abstract][Full Text] [Related]
18. Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A.
Shang ES; Champion CI; Wu XY; Skare JT; Blanco DR; Miller JN; Lovett MA
Infect Immun; 2000 Jul; 68(7):4189-99. PubMed ID: 10858236
[TBL] [Abstract][Full Text] [Related]
19. Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.
Sadziene A; Barbour AG
Infection; 1996; 24(2):195-202. PubMed ID: 8740122
[TBL] [Abstract][Full Text] [Related]
20. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
